Qlife Holding AB (QLIFE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Qlife Holding AB (QLIFE) has a cash flow conversion efficiency ratio of -2.207x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-4.20 Million ≈ $-452.42K USD) by net assets (Skr1.91 Million ≈ $205.01K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Qlife Holding AB balance sheet independence to measure how much of total assets are equity-financed.
Qlife Holding AB - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Qlife Holding AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check QLIFE capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Qlife Holding AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Qlife Holding AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
E-Pango SA
PA:ALAGO
|
0.796x |
|
Adial Pharmaceuticals Inc
NASDAQ:ADIL
|
-0.434x |
|
Adcore Inc
TO:ADCO
|
0.406x |
|
Trinity Freehold & Leasehold PRP Fund
BK:TNPF
|
0.002x |
|
LCK Global Kedaton
JK:LCKM
|
0.002x |
|
Haidemenos S.A.
AT:HAIDE
|
0.043x |
|
TME PHARM.CONF.IPO EO 1-
F:0N6A
|
N/A |
|
Daesang Holdings Co Ltd Pref
KO:084695
|
0.058x |
Annual Cash Flow Conversion Efficiency for Qlife Holding AB (2019–2025)
The table below shows the annual cash flow conversion efficiency of Qlife Holding AB from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Qlife Holding AB worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr-7.51 Million ≈ $-807.98K |
Skr-15.60 Million ≈ $-1.68 Million |
2.077x | -92.06% |
| 2024-12-31 | Skr-1.43 Million ≈ $-153.78K |
Skr-37.37 Million ≈ $-4.02 Million |
26.151x | +1346.70% |
| 2023-12-31 | Skr-23.12 Million ≈ $-2.49 Million |
Skr-41.80 Million ≈ $-4.50 Million |
1.808x | +445.18% |
| 2022-12-31 | Skr91.15 Million ≈ $9.81 Million |
Skr-47.73 Million ≈ $-5.14 Million |
-0.524x | -228.02% |
| 2021-12-31 | Skr163.18 Million ≈ $17.56 Million |
Skr-26.05 Million ≈ $-2.80 Million |
-0.160x | +15.05% |
| 2020-12-31 | Skr89.55 Million ≈ $9.64 Million |
Skr-16.83 Million ≈ $-1.81 Million |
-0.188x | -202.62% |
| 2019-12-31 | Skr62.48 Million ≈ $6.72 Million |
Skr-3.88 Million ≈ $-417.54K |
-0.062x | -- |
About Qlife Holding AB
Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents in Sweden. The company offers Egoo.Health Platform, a product platform that enables advanced biomarker testing, consisting of a small device, disposable capsules, and the supplementing software. Qlife Holding AB (publ) was incorporated in 2019 and is based in Gothenburg, Sweden.